Praxis Precision Medicines Reveals POWER1 Study Outcomes for Focal Onset Seizures
Praxis Precision Medicines (PRAX) has released the findings from its Phase 2/3 POWER1 study, evaluating vormatrigine for focal onset seizures. While primary efficacy goals were not fully met, the study demonstrated positive effectiveness in higher doses, alongside a favorable safety profile and low patient discontinuation rates. The company plans to leverage these insights for future drug development and remains committed to commercializing other key therapies.





